US 12,281,127 B2
Pyrido[4,3-d]pyrimidine compounds
Benjamin Joseph Burke, San Diego, CA (US); Jacob Cole Deforest, San Diego, CA (US); Asako Nagata, San Diego, CA (US); Simon Paul Planken, San Marcos, CA (US); Jillian Elyse Spangler, San Diego, CA (US); Scott Channing Sutton, San Diego, CA (US); Hanna Maria Wisniewska, San Diego, CA (US); and Shouliang Yang, San Diego, CA (US)
Assigned to Pfizer Inc., New York, NY (US)
Filed by PFIZER INC., New York, NY (US)
Filed on Oct. 1, 2024, as Appl. No. 18/903,345.
Application 18/903,345 is a continuation of application No. 18/625,795, filed on Apr. 3, 2024.
Claims priority of provisional application 63/568,399, filed on Mar. 21, 2024.
Claims priority of provisional application 63/550,564, filed on Feb. 6, 2024.
Claims priority of provisional application 63/598,907, filed on Nov. 14, 2023.
Claims priority of provisional application 63/540,044, filed on Sep. 22, 2023.
Claims priority of provisional application 63/507,621, filed on Jun. 12, 2023.
Claims priority of provisional application 63/494,346, filed on Apr. 5, 2023.
Prior Publication US 2025/0034173 A1, Jan. 30, 2025
Int. Cl. C07D 519/00 (2006.01); A61K 31/553 (2006.01); A61P 35/00 (2006.01)
CPC C07D 519/00 (2013.01) [A61K 31/553 (2013.01); A61P 35/00 (2018.01)] 9 Claims
 
1. A compound selected from the group consisting of:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.